Author Archives: Steve Bryson PhD

Pooled Trial Analysis Confirms Efficacy, Safety of Firdapse in Adults

Firdapse (amifampridine) improved muscle strength and response to nerve cell stimulation in adults with Lambert-Eaton myasthenic syndrome (LEMS), a pooled analysis of six clinical trials demonstrated. The findings showed that all six previous trials together “showed significant efficacy, consistent with earlier reports of beneficial efficacy” of Firdapse —…

Patient-reported Data Reliable, Dutch Analysis Finds

Almost all people with Lambert-Eaton myasthenic syndrome (LEMS) have generalized symptoms at disease onset, according to an analysis of data from a Dutch patient registry. That finding, and others, were similar between patient-completed questionnaires and medical records, which supported…

LEMS Treatments Don’t Affect Calcium Channels, Study Finds

The molecule 3,4-diaminopyridine (3,4-DAP) — approved as Firdapse and Ruzurgi to treat people with Lambert-Eaton myasthenic syndrome (LEMS) — works to directly induce the release of chemical messengers by binding to potassium channels, without affecting calcium channels as previously thought, a study reported. …